(SRPT) Sarepta Therapeutics - Ratings and Ratios
Gene Therapy, Antisense, Duchenne, Exon Skipping
SRPT EPS (Earnings per Share)
SRPT Revenue
Description: SRPT Sarepta Therapeutics
Sarepta Therapeutics Inc (NASDAQ:SRPT) is a biotechnology company listed on the NASDAQ stock exchange. The companys stock is classified under the GICS Sub Industry of Biotechnology, indicating its primary focus on developing treatments for rare diseases.
To evaluate SRPTs financial health, we can examine key performance indicators (KPIs) such as revenue growth, net income, and operating expenses. The companys income tax expense is a relevant metric, as it can impact net income and cash flows. A thorough analysis of SRPTs tax strategy and its impact on profitability is essential.
SRPTs market capitalization is approximately $1.68 billion, suggesting a moderate level of market presence. The forward price-to-earnings (P/E) ratio is around 9.84, indicating that investors expect the company to generate earnings in the future. However, the current P/E ratio is not available, likely due to the companys current net loss. The return on equity (RoE) is -20.00%, highlighting the companys current unprofitability.
Key economic drivers for SRPT include the development and commercialization of its pipeline products, particularly in the rare disease space. The companys ability to secure regulatory approvals, manage clinical trials, and navigate the competitive landscape will significantly impact its financial performance. Additionally, SRPTs cash burn rate, research and development expenses, and potential partnerships or collaborations will influence its financial trajectory.
To make informed investment decisions, it is crucial to monitor SRPTs progress in its clinical trials, regulatory updates, and financial performance. A detailed analysis of the companys cash flows, operating expenses, and revenue growth will provide valuable insights into its potential for future profitability.
SRPT Stock Overview
| Market Cap in USD | 1,681m |
| Sector | Healthcare |
| Industry | Biotechnology |
| GiC Sub-Industry | Biotechnology |
| IPO / Inception | 1997-06-03 |
SRPT Stock Ratings
| Growth Rating | -64.4 |
| Fundamental | 27.4% |
| Dividend Rating | - |
| Rel. Strength | -83.9 |
| Analysts | 4.38 of 5 |
| Fair Price Momentum | 17.04 USD |
| Fair Price DCF | - |
SRPT Dividends
Currently no dividends paidSRPT Growth Ratios
| Growth Correlation 3m | -82.3% |
| Growth Correlation 12m | -94.7% |
| Growth Correlation 5y | 3.7% |
| CAGR 5y | -35.38% |
| CAGR/Max DD 5y | -0.38 |
| Sharpe Ratio 12m | -0.87 |
| Alpha | -110.32 |
| Beta | 1.231 |
| Volatility | 65.44% |
| Current Volume | 11116.4k |
| Average Volume 20d | 16233.9k |
| Stop Loss | 16.6 (-7.5%) |
Piotroski VR‑10 (Strict, 0-10) 2.0
| Net Income (-248.4m TTM) > 0 and > 6% of Revenue (6% = 134.0m TTM) |
| FCFTA -0.10 (>2.0%) and ΔFCFTA 8.36pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 81.80% (prev 132.3%; Δ -50.47pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.16 (>3.0%) and CFO -547.1m <= Net Income -248.4m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 4.02 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (97.4m) change vs 12m ago -1.77% (target <= -2.0% for YES) |
| Gross Margin 81.43% (prev 88.18%; Δ -6.75pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 66.77% (prev 43.52%; Δ 23.25pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -8.79 (EBITDA TTM -117.7m / Interest Expense TTM 18.7m) >= 6 (WARN >= 3) |
Altman Z'' -3.36
| (A) 0.53 = (Total Current Assets 2.43b - Total Current Liabilities 605.6m) / Total Assets 3.47b |
| (B) -1.34 = Retained Earnings (Balance) -4.66b / Total Assets 3.47b |
| warn (B) unusual magnitude: -1.34 — check mapping/units |
| (C) -0.05 = EBIT TTM -164.6m / Avg Total Assets 3.34b |
| (D) -2.01 = Book Value of Equity -4.66b / Total Liabilities 2.32b |
| Total Rating: -3.36 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 27.42
| 1. Piotroski 2.0pt = -3.0 |
| 2. FCF Yield -11.81% = -5.0 |
| 3. FCF Margin -15.35% = -5.75 |
| 4. Debt/Equity 1.53 = 1.44 |
| 5. Debt/Ebitda -14.81 = -2.50 |
| 6. ROIC - WACC -12.08% = -12.50 |
| 7. RoE -20.00% = -2.50 |
| 8. Rev. Trend 94.78% = 4.74 |
| 9. Rev. CAGR 47.21% = 2.50 |
| 10. EPS Trend data missing |
| 11. EPS CAGR 0.0% = 0.0 |
As of August 13, 2025, the stock is trading at USD 17.94 with a total of 11,116,429 shares traded.
Over the past week, the price has changed by +12.24%, over one month by -2.24%, over three months by -48.31% and over the past year by -85.39%.
No, based on ValueRay´s Fundamental Analyses, Sarepta Therapeutics (NASDAQ:SRPT) is currently (August 2025) a stock to sell. It has a ValueRay Fundamental Rating of 27.42 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of SRPT is around 17.04 USD . This means that SRPT is currently overvalued and has a potential downside of -5.02%.
Sarepta Therapeutics has received a consensus analysts rating of 4.38. Therefore, it is recommended to buy SRPT.
- Strong Buy: 14
- Buy: 8
- Hold: 4
- Sell: 0
- Strong Sell: 0
According to our own proprietary Forecast Model, SRPT Sarepta Therapeutics will be worth about 18.4 in August 2026. The stock is currently trading at 17.94. This means that the stock has a potential upside of +2.73%.
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 22.2 | 23.5% |
| Analysts Target Price | 90 | 401.4% |
| ValueRay Target Price | 18.4 | 2.7% |
SRPT Fundamental Data Overview
CCE Cash And Equivalents = 522.8m USD (Cash And Short Term Investments, last quarter)
P/E Forward = 9.8425
P/S = 0.7525
P/B = 1.3674
P/EG = 159.25
Beta = 0.455
Revenue TTM = 2.23b USD
EBIT TTM = -164.6m USD
EBITDA TTM = -117.7m USD
Long Term Debt = 1.14b USD (from longTermDebt, last quarter)
Short Term Debt = 605.6m USD (from totalCurrentLiabilities, last quarter)
Debt = 1.74b USD (Calculated: Short Term 605.6m + Long Term 1.14b)
Net Debt = 1.10b USD (from netDebt column, last quarter)
Enterprise Value = 2.90b USD (1.68b + Debt 1.74b - CCE 522.8m)
Interest Coverage Ratio = -8.79 (Ebit TTM -164.6m / Interest Expense TTM 18.7m)
FCF Yield = -11.81% (FCF TTM -342.7m / Enterprise Value 2.90b)
FCF Margin = -15.35% (FCF TTM -342.7m / Revenue TTM 2.23b)
Net Margin = -11.12% (Net Income TTM -248.4m / Revenue TTM 2.23b)
Gross Margin = 81.43% ((Revenue TTM 2.23b - Cost of Revenue TTM 414.8m) / Revenue TTM)
[93m Tobins Q-Ratio = -0.62 (set to none) (Enterprise Value 2.90b / Book Value Of Equity -4.66b)
[39m Interest Expense / Debt = 0.26% (Interest Expense 4.50m / Debt 1.74b)
Taxrate = 9.79% (from yearly Income Tax Expense: 25.5m / 260.8m)
NOPAT = -164.6m (EBIT -164.6m, no tax applied on loss)
Current Ratio = 4.02 (Total Current Assets 2.43b / Total Current Liabilities 605.6m)
Debt / Equity = 1.53 (Debt 1.74b / last Quarter total Stockholder Equity 1.14b)
Debt / EBITDA = -14.81 (Net Debt 1.10b / EBITDA -117.7m)
Debt / FCF = -5.09 (Debt 1.74b / FCF TTM -342.7m)
Total Stockholder Equity = 1.24b (last 4 quarters mean)
RoA = -7.17% (Net Income -248.4m, Total Assets 3.47b )
RoE = -20.00% (Net Income TTM -248.4m / Total Stockholder Equity 1.24b)
RoCE = -6.91% (Ebit -164.6m / (Equity 1.24b + L.T.Debt 1.14b))
RoIC = -6.79% (NOPAT -164.6m / Invested Capital 2.42b)
WACC = 5.30% (E(1.68b)/V(3.42b) * Re(10.55%)) + (D(1.74b)/V(3.42b) * Rd(0.26%) * (1-Tc(0.10)))
Shares Correlation 5-Years: 70.0 | Cagr: 4.04%
Discount Rate = 10.55% (= CAPM, Blume Beta Adj.)
[93m Fair Price DCF = unknown (Cash Flow -342.7m)
[39m Revenue Correlation: 94.78 | Revenue CAGR: 47.21%
Revenue Growth Correlation: 73.39%
EPS Correlation: N/A | EPS CAGR: 0.0%
EPS Growth Correlation: -32.28%
Additional Sources for SRPT Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle